TrkA 

 74 Products   74 Products   309 Diseases   14427 News 


«12345678910111213...169170»
  • ||||||||||  Journal:  Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC. (Pubmed Central) -  Mar 13, 2025   
    The analysis demonstrated the strong benefits of repotrectinib in PFS, which was robust across different SAs and supported by numerically favorable results for DoR (where available) and ORR. These results, alongside the published TRIDENT-1 clinical data, further support repotrectinib as a potential new standard of care for TKI-na
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Biomarker, Trial completion, Trial primary completion date:  RegoRec: Biomolecular Analysis for Predicting Response to Regorafenib (clinicaltrials.gov) -  Mar 13, 2025   
    P=N/A,  N=53, Completed, 
    These results, alongside the published TRIDENT-1 clinical data, further support repotrectinib as a potential new standard of care for TKI-na Recruiting --> Completed | Trial primary completion date: Jun 2024 --> Sep 2024
  • ||||||||||  Mizollen (mizolastine) / Sanofi, Mitsubishi Tanabe, Vitrakvi (larotrectinib) / Bayer
    Preclinical, Journal:  Discovery of Non-Steroidal Aldo-Keto Reductase 1D1 Inhibitors through Automated Screening and In Vitro Evaluation. (Pubmed Central) -  Mar 12, 2025   
    The structural diversity of the identified inhibitors demonstrates that the binding site of AKR1D1 is rather promiscuous and can accommodate a broad range of ligands. These findings underscore the importance of toxicity screening and potential to identify structurally different AKR1D1 inhibitors.
  • ||||||||||  Vitrakvi (larotrectinib) / Bayer
    Journal, MSi-H Biomarker:  Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer. (Pubmed Central) -  Mar 12, 2025   
    P2
    Larotrectinib demonstrated long durability, extended survival and manageable safety in patients with TRK fusion GI cancer, including those with MSI-H CRC. This supports the wider adoption of next-generation sequencing testing for NTRK gene fusions in patients with GI cancer.
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Gavreto (pralsetinib) / Rigel, Tafinlar (dabrafenib) / Novartis
    FDA event, Journal, Monotherapy:  Monotherapy vs combination therapy evaluation of FDA-approved TKIs targeting PDGFR for the treatment of thyroid cancer. (Pubmed Central) -  Mar 10, 2025   
    On 4th May, 2018, a combination of Dabrafenib and Trametinib/Dab-Tra has been approved by US FDA for the treatment of anaplastic thyroid cancer (ATC) that highlights the importance of combination therapy in its treatment...We found that the best combination amongst all is of Pralsetinib and Trametinib/Pra-Tra with a docking score of -14.47?kcal/mol...We also found that a combinatorial approach with TKIs could prove to be better than monotherapy. Further in-vitro and in-vivo studies are required to strengthen the results obtained through in-silico experiment.
  • ||||||||||  Biomarker, Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, Pan tumor:  Pan-Cancer Molecular Biomarkers: Practical Considerations for the Surgical Pathologist. (Pubmed Central) -  Mar 10, 2025   
    Several other biomarkers are currently under investigation including FGFR, RET, and ROS1 fusions; ERBB2 amplification; and mutations in the AKT1/2/3, NF1, RAS pathway, and MAPK pathway. As molecular assays are increasingly incorporated into routine tumor workup, the emergence of additional pan-cancer biomarkers is likely to be a matter more of "when" than "if." In this review, we first explore some of the conceptual and technical considerations at the intersection of surgical and molecular pathology, followed by a brief overview of both established and emerging molecular pan-cancer biomarkers and their diagnostic and clinical applications.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Preclinical, Journal:  Regorafenib as a potential drug for severe COVID-19: inhibition of inflammasome activation in mice. (Pubmed Central) -  Mar 10, 2025   
    Notably, regorafenib inhibited NLR family pyrin domain containing 3 (NLRP3) inflammasome activation, a key driver of the cytokine storm associated with severe COVID-19. Our findings elucidate the molecular mechanisms underlying therapeutic effects of regorafenib and suggest its potential use as a promising treatment option for severe COVID-19.
  • ||||||||||  Rozlytrek (entrectinib) / Roche, Alecensa (alectinib) / Roche
    HORIZON-01: a phase I (0) -  Mar 7, 2025 - Abstract #BTOG2025BTOG_408;    
    P2, P3
    Eligible patients are randomised 1: 1 to receive durvalumab (one year) or targeted therapy (three years) including alectinib (ALK+) or entrectinib (ROS1+), until disease progression, maximum treatment duration, unacceptable toxicity, consent withdrawal, or death. N/A.
  • ||||||||||  Rozlytrek (entrectinib) / Roche, Inqovi (decitabine/cedazuridine) / Otsuka
    Trial completion date, Trial primary completion date:  Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia (clinicaltrials.gov) -  Mar 5, 2025   
    P1,  N=12, Recruiting, 
    Trk receptor inhibition could be an effective modality for the treatment of SCI-related neurogenic LUTD such as DO and DSD. Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Enrollment closed, Trial primary completion date:  Cabozantinib in Combo with NIVO + IPI in Advanced NCCRCC (clinicaltrials.gov) -  Mar 3, 2025   
    P2,  N=60, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2024 --> Jun 2025
  • ||||||||||  Vitrakvi (larotrectinib) / Bayer
    Review, Journal:  NTRK rearranged spindle cell neoplasm of the uterine cervix: a rare case report and literature review. (Pubmed Central) -  Feb 27, 2025   
    The most prevalent type of gene fusion was TPM3-NTRK1, and almost all cases demonstrated S-100 and CD34 positivity by IHC. Surgery remains the initial treatment of choice and tyrosine receptor kinase (TRK) inhibitors may serve as a promising target therapy for patients with recurred or metastatic disease.
  • ||||||||||  Journal, Adverse events:  HOPIPRAC: Pharmacovigilance interface for detecting cases of adverse events in a hospital data warehouse (Pubmed Central) -  Feb 27, 2025   
    The HOPIPRAC interface gives pharmacovigilants autonomy in monitoring drug risk in healthcare institutions, in addition to spontaneous notification. Querying a more advanced warehouse that collects multimodal data, and deploying it on a wider regional or even national scale, will help to overcome some of the limitations of the current warehouse.
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Cabometyx (cabozantinib tablet) / Exelixis, Tecentriq (atezolizumab) / Roche
    Trial primary completion date:  Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial (clinicaltrials.gov) -  Feb 24, 2025   
    P2,  N=33, Recruiting, 
    Our findings confirm the existence of ETV6-NTRK3 fusion GIST and demonstrate that these imatinib-resistant GISTs may be exquisitely sensitive to TRK. Trial primary completion date: Jan 2025 --> Apr 2025